Alkermes plc (Nasdaq: ALKS) today announced that nemvaleukin alfa (“nemvaleukin", formerly referred to as ALKS 4230), the company’s investigational engineered interleukin-2 (IL-2) variant immunotherapy, has been granted orphan drug designation for the treatment of mucosal melanoma by the U.S. Food and Drug Administration (FDA).
Publications
Preoperative ultrasound assessment of regional lymph nodes in melanoma patients does not provide reliable nodal staging: Results from a large multicenter trial
This study was undertaken to determine if preoperative ultrasound (US) assessment of regional lymph nodes in patients who present with primary cutaneous melanoma provides accurate staging.
The worse survival outcomes reported for melanoma patients having sentinel node biopsy after lymphoscintigraphy the previous day do not appear to be due to overnight migration of Tc99m-nanocolloid tracer
Patients having sentinel node (SN) biopsy for melanoma the day after lymphoscintigraphy using Tc99m-nanocolloid are reported to have worse survival outcome than that of patients having lymphoscintigraphy and SN biopsy on the same day.
Optimising prediction of early metastasis-free survival in uveal melanoma using a four-category model incorporating gene expression profile and tumour size
Since largest basal diameter (LBD) seems to have independent prognostic worth in uveal melanoma (UM), this topic is further studied herein among all patients undergoing plaque brachytherapy or enucleation for UM involving the choroid and/or ciliary body between 2012 and 2019.